Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647581 · ClinicalTrials.gov registry record · NA
Risk of Post-polypectomy Bleeding With Prophylactic Hemoclipping
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 11,182
- Enrollment target
NCT01647581: Completed NA study, sponsored by VA Office of Research and Development.
NCT01647581 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 11,182 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (697% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01647581, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 11,182 participants
- Enrollment target
Study Summary
A randomized trial aimed at determining whether or not hemoclips are effective in preventing post-polypectomy bleeds on polyps that are 10mm in size or greater.
Primary Outcome
rectal bleeding with associated Hb 2g drop, hemodynamic instability, or need for repeat colonoscopy or angiography or surgery
Interventions
- DEVICE Hemoclip Placement
- DEVICE NO hemoclip placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,182 participants |
| Start Date | 2011-09-01 |
| Est. Completion | 2018-11-01 |
| Phase | NA |
What the finished NCT01647581 record still lists
NCT01647581 is an interventional study that assigns participants to a tested intervention. Its 11,182 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (697% higher).
The record links to 0 conditions, and to 2 interventions - of which Hemoclip Placement is the first listed.
NCT01647581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01647581 about?
NCT01647581 is a clinical study titled "Risk of Post-polypectomy Bleeding With Prophylactic Hemoclipping". A randomized trial aimed at determining whether or not hemoclips are effective in preventing post-polypectomy bleeds on polyps that are 10mm in size or greater.
What is the current status of trial NCT01647581?
This trial is currently completed. It is a NA study. The enrollment target is 11,182 participants. The study started on 2011-09-01. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT01647581?
The interventions under investigation include: Hemoclip Placement (DEVICE), NO hemoclip placement (DEVICE).
Who is sponsoring clinical trial NCT01647581?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01647581's enrollment target sits among peer trials
11,182 14th of 2000 higher than 1,987 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI